Table 2.
Multivariate analysis of factors affecting PSA recurrence-free survival.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age ≤ 70 y.o. | 1.167 (0.707–1.926) | 0.546 | ||
| Initial PSA ≤ 20 ng/ml | 0.610 (0.255–1.050) | 0.074 | 0.795 (0.501–1.261) | 0.329 |
| T stage ≤ T2c | 0.673 (0.292–1.156) | 0.151 | ||
| Gleason score ≤ 7 | 0.581 (0.332–0.018) | 0.058 | 0.872 (0.594–1.281) | 0.485 |
| NCCN risk factor = 1 | 0.423 (0.242–0.741) | 0.003 | 1.249 (0.766–2.036) | 0.374 |
| Anti-androgen + | 0.602 (0.360–1.005) | 0.052 | 1.036 (0.663–1.621) | 0.876 |
| Pre-RT PSA < 0.2 ng/ml | 0.418 (0.249–0.702) | 0.001 | 0.848 (0.580–1.240) | 0.394 |
| NAHT ≤ 6mo | 0.730 (0.428–1.244) | 0.247 | ||